In2Pharma
  • Home
  • Services
    • Regulatory Affairs
    • Quality Assurance
    • Publicity and Compliance
    • Medical writing & training
    • Vigilance
  • About Us
  • News
  • Contact
Select Page

The Dutch authorities will compensate companies for additional costs due to the Falsified Medicines Directive

by In2Pharma | Dec 5, 2018 | News

The Netherlands As a result of the Falsified Medicines Directive, companies are obliged to adapt the packaging of their medicines which leads to additional costs. These additional costs cannot always be compensated by a price increase, due to the Drug Price Act (Wet...

Recent Posts

  • Junior Consultant vacancy
  • Register your Industry Single Point of Contact (i-SPOC) on supply and availability
  • Update Commission Regulation regarding monacolins from red yeast rice
  • The FAMHP launches the Medicinal Product Management database
  • Request to marketing authorisation holders to send the approved version of the risk management plan

Follow Us

  • Facebook
  • LinkedIn
Privacy Policy | Cookie Policy | BTW BE 895730662 | +32 16 89 16 00| info@in2pharma.com | Terloonststraat 22, 1910 Kampenhout, België